

## **Tirzepatide (Mounjaro®) use for weight loss BNSSG ICS update**

Following [NICE's announcement on tirzepatide](#) in December 2024, and the publication of NICE guideline [NG246: Overweight and obesity management](#) in January 2025, we are working with our system partners in Bristol, North Somerset and South Gloucestershire (BNSSG) to follow guidance from NICE and NHS England to make tirzepatide available for weight management.

We know there are many eligible people who would like NHS access to this medication as soon as possible but, in line with the [phased national rollout](#), tirzepatide will not immediately be available to everyone who wishes to use it. Tirzepatide will initially be offered to individuals facing the most significant health risks related to their weight, starting in spring 2025 through Specialist Weight Management Services (SWMS). This will include prioritising people already receiving care in SWMS.

We ask for patience whilst we wait for further communication from NHSE on how access to tirzepatide will be rolled out at scale and while we establish the best way to meet our local needs.

**We are asking our GPs not to prescribe tirzepatide for weight loss yet**, while we work with clinical experts to develop options for new local services that will offer tirzepatide in primary care by summer 2025.

**A series of FAQs have been published for Healthcare Professionals [here](#) and for patients [here](#).** These will be regularly updated as we receive further information from NHS England on funding arrangements, prioritisation groups and details on the 'wraparound care' element required by NICE guidance. Wraparound care focuses on diet, nutrition and increasing physical activity and may include programmes delivered digitally and/or in person.